89 related articles for article (PubMed ID: 19667499)
1. Efficacy and tolerability of short-term venlafaxine XR therapy for GAD. Results of short-term, double-blind, placebo-controlled trials.
Feighner J
Postgrad Med; 1999 Nov; 106(6 Suppl):10-6. PubMed ID: 19667499
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies.
Lydiard RB
Postgrad Med; 1999 Nov; 106(6 Suppl):17-23. PubMed ID: 19667500
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
5. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
[TBL] [Abstract][Full Text] [Related]
7. Venlafaxine XR in the treatment of anxiety.
Hackett D
Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
9. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
Meoni P; Salinas E; Brault Y; Hackett D
J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
[TBL] [Abstract][Full Text] [Related]
10. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis.
Montgomery SA; Mahé V; Haudiquet V; Hackett D
J Clin Psychopharmacol; 2002 Dec; 22(6):561-7. PubMed ID: 12454555
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
Sussman N
Postgrad Med; 1999 Nov; 106(6 Suppl):31-6. PubMed ID: 19667502
[TBL] [Abstract][Full Text] [Related]
13. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
15. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Sheehan DV
J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
[TBL] [Abstract][Full Text] [Related]
16. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.
Li X; Zhu L; Su Y; Fang S
PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121
[TBL] [Abstract][Full Text] [Related]
18. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Rickels K; Pollack MH; Sheehan DV; Haskins JT
Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
Sheehan DV
J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
